4.79
1.24%
-0.06
After Hours:
4.76
-0.03
-0.63%
Vanda Pharmaceuticals Inc stock is traded at $4.79, with a volume of 587.35K.
It is down -1.24% in the last 24 hours and up +3.46% over the past month.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.
See More
Previous Close:
$4.85
Open:
$4.8
24h Volume:
587.35K
Relative Volume:
1.04
Market Cap:
$279.21M
Revenue:
$192.64M
Net Income/Loss:
$2.51M
P/E Ratio:
17.74
EPS:
0.27
Net Cash Flow:
$12.42M
1W Performance:
+2.13%
1M Performance:
+3.46%
6M Performance:
-1.84%
1Y Performance:
+5.97%
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Name
Vanda Pharmaceuticals Inc
Sector
Industry
Phone
202-734-3400
Address
2200 PENNSYLVANIA AVE NW, WASHINGTON
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-11-24 | Initiated | Cantor Fitzgerald | Overweight |
Feb-25-22 | Downgrade | Jefferies | Buy → Hold |
May-12-21 | Initiated | BofA Securities | Buy |
Jan-14-21 | Downgrade | Citigroup | Buy → Neutral |
Oct-29-20 | Upgrade | Citigroup | Neutral → Buy |
Jun-09-20 | Downgrade | Citigroup | Buy → Neutral |
Mar-16-20 | Downgrade | Oppenheimer | Perform → Underperform |
Mar-12-20 | Upgrade | Citigroup | Neutral → Buy |
Nov-07-19 | Downgrade | Citigroup | Buy → Neutral |
Aug-01-19 | Upgrade | Citigroup | Neutral → Buy |
Jul-25-19 | Downgrade | Stifel | Buy → Hold |
Dec-11-18 | Downgrade | Oppenheimer | Outperform → Perform |
Dec-04-18 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
Dec-04-18 | Reiterated | Jefferies | Buy |
Nov-08-18 | Resumed | Jefferies | Buy |
Sep-21-18 | Resumed | Oppenheimer | Outperform |
May-23-18 | Initiated | Citigroup | Buy |
Jan-19-18 | Initiated | Seaport Global Securities | Buy |
Sep-14-17 | Reiterated | Piper Jaffray | Overweight |
Jun-27-17 | Resumed | Piper Jaffray | Overweight |
May-26-17 | Initiated | H.C. Wainwright | Buy |
Apr-12-17 | Initiated | Oppenheimer | Outperform |
Nov-09-16 | Initiated | Aegis Capital | Buy |
Oct-06-16 | Resumed | Jefferies | Buy |
View All
Vanda Pharmaceuticals Inc Stock (VNDA) Latest News
Gastroparesis Drugs Market to Grow by USD 1.42 Billion from 2024-2028, Driven by Rising Diabetes Rates and AI-Driven Market Trend InsightsTechnavio - The Malaysian Reserve
Vanda Pharmaceuticals Leads The Pack Of 3 US Penny Stocks - Simply Wall St
Brokers Set Expectations for VNDA Q3 Earnings - MarketBeat
Vanda started at buy by H.C. Wainwright, negative enterprise value cited - MSN
Over 200% Stock UpsideVanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst - Yahoo Finance
Brokers Issue Forecasts for VNDA FY2024 Earnings - MarketBeat
StockNews.com Begins Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) - MarketBeat
Vanda Pharmaceuticals (VNDA) Set to Announce Quarterly Earnings on Wednesday - MarketBeat
Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Buy Rating from Analysts at HC Wainwright - MarketBeat
VNDAVanda Pharmaceuticals Inc. Latest Stock News & Market Updates - StockTitan
Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024 - StockTitan
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Sees Significant Growth in Short Interest - MarketBeat
Vanda Pharmaceuticals (NASDAQ:VNDA) Coverage Initiated at StockNews.com - MarketBeat
Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More - MSN
Allergic Conjunctivitis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO - The Globe and Mail
Vanda Pharma soars as Cycle Pharma reiterates $8/share offer (update) - MSN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc.VNDA - PR Newswire
Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Hold Rating from Analysts at StockNews.com - MarketBeat
VNDA Rejects Second Takeover Bid by Cycle Group, Stock Rises - Yahoo Finance
Cycle Pharmaceuticals reaffirms proposal to acquire Vanda Pharmaceuticals - Yahoo Finance
D.C. drugmaker Vanda rejects another acquisition offer - The Business Journals
Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share - BioSpace
Cycle Pharmaceuticals Makes Bold Move To Acquire Vanda Pharma - Finimize
Vanda Pharmaceuticals rejects Cycle Pharma's second takeover offer - Reuters
Vanda Pharmaceuticals Rejects Deal Proposal From Cycle Group - MarketWatch
Cycle Pharmaceuticals Stands By $488 Million Offer for Vanda - Yahoo Finance
Vanda Pharmaceuticals rejects Cycle Group's $8.00 per share bid - Investing.com
Cycle Pharma maintains takeover offer for Vanda Pharmaceuticals - WHBL
Vanda Pharmaceuticals rejects Cycle Group's $8.00 per share bid By Investing.com - Investing.com UK
Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd. - PR Newswire
Vanda Pharma stock soars as Cycle Pharma reiterates $8/share offer - Seeking Alpha
Cycle Pharmaceuticals offers $8 per share for Vanda By Investing.com - Investing.com UK
Cycle Pharma Is Said to Stand By $488 Million Offer for Vanda - AllSides
Cycle Pharmaceuticals Limited cancelled the acquisition of Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA for approximately $490 million. - Marketscreener.com
Profit Investment Management LLC Lowers Stock Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat
Squarepoint Ops LLC Decreases Stock Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat
Schizophrenia Clinical Trial Pipeline Insights Featuring 55+ Companies | DelveInsight - GlobeNewswire Inc.
US Supreme Court reportedly declines to hear Vanda patent case - MSN
Dimensional Fund Advisors LP Purchases 292,172 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat
Sei Investments Co. Sells 123,694 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat
Vanda Pharmaceuticals updates bylaws, clarifies stockholder meetings By Investing.com - Investing.com Canada
Vanda Pharmaceuticals updates bylaws, clarifies stockholder meetings - Investing.com India
Vanda Pharmaceuticals Inc Stock (VNDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):